
Tevogen Bio Holdings, a clinical-stage biotech company specialising in immunotherapy, has expanded collaboration with Microsoft to further develop Tevogen Bio’s proprietary PredicTcell technology, which focuses on predictive precision T-cell targeting.
The collaboration will utilise Microsoft’s artificial intelligence (AI) capabilities, cloud infrastructure, and expertise in health and life sciences to accelerate target identification and pre-clinical processes. Tevogen Bio anticipates that this will strengthen its pipeline of immunotherapy products.
Under Tevogen Bio’s AI initiative, Tevogen.AI, Microsoft’s advanced AI tools and the Azure cloud platform will be integrated.
Tevogen Bio plans to leverage machine learning to perform simulations that expedite the identification of new therapeutic targets. Following the successful trial of its TVGN 489 product, the company will use Microsoft’s AI to process large genomic datasets with increased speed and precision.
The partnership will also focus on creating algorithms to decode interactions between human leukocyte antigens (HLA) and T cells. This is expected to enhance Tevogen Bio’s understanding of immune responses and open up new therapeutic opportunities, particularly in areas where limited data exists.
Additionally, Tevogen Bio is applying this AI-driven approach to the development of potential treatments for Human Papillomavirus (HPV).
Using the Microsoft Azure platform, the company has developed a dataset of HPV proteins and is identifying cytotoxic T cell (CTL) targets. These efforts are intended to support a clinical trial for TVGN 920, Tevogen Bio’s first oncology product candidate.
The ExacTcell technology, which trains CTLs to detect specific targets before expanding them for therapeutic use, underpins Tevogen Bio’s strategy to deliver an HPV-specific CTL treatment.
Tevogen Bio CIO and Tevogen.AI head Mittul Mehta said: “As we expand our AI efforts, this broader relationship with Microsoft represents a key milestone in our ongoing journey to revolutionise immunotherapy.
“Through deeper collaboration with Microsoft domain experts, we will further harness the power of AI to bring more precise and personalised treatments to patients at an accelerated pace.”